BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28984201)

  • 1. Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets.
    Kuznetsov VA; Tang Z; Ivshina AV
    BMC Genomics; 2017 Oct; 18(Suppl 6):692. PubMed ID: 28984201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
    Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
    Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of microRNA expression in serous ovarian carcinoma.
    Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
    Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The modularity and dynamicity of miRNA-mRNA interactions in high-grade serous ovarian carcinomas and the prognostic implication.
    Zhang W; Edwards A; Fan W; Flemington EK; Zhang K
    Comput Biol Chem; 2016 Aug; 63():3-14. PubMed ID: 26949157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression.
    Faggad A; Budczies J; Tchernitsa O; Darb-Esfahani S; Sehouli J; Müller BM; Wirtz R; Chekerov R; Weichert W; Sinn B; Mucha C; Elwali NE; Schäfer R; Dietel M; Denkert C
    J Pathol; 2010 Feb; 220(3):382-91. PubMed ID: 19960504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
    Li Q; Xiao X; Feng J; Yan R; Xi J
    Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
    Gu Y; Zhang M; Peng F; Fang L; Zhang Y; Liang H; Zhou W; Ao L; Guo Z
    Oncotarget; 2015 Feb; 6(4):2397-406. PubMed ID: 25537514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.
    Koutsaki M; Spandidos DA; Zaravinos A
    Cancer Lett; 2014 Sep; 351(2):173-81. PubMed ID: 24952258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple signatures of a disease in potential biomarker space: Getting the signatures consensus and identification of novel biomarkers.
    Ow GS; Kuznetsov VA
    BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S2. PubMed ID: 26100469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer.
    Ray M; Ruffalo MM; Bar-Joseph Z
    Genes Chromosomes Cancer; 2019 Jan; 58(1):34-42. PubMed ID: 30285311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
    Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
    Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNA and Ovarian Cancer.
    Langhe R
    Adv Exp Med Biol; 2015; 889():119-51. PubMed ID: 26659000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer.
    Aboutalebi H; Bahrami A; Soleimani A; Saeedi N; Rahmani F; Khazaei M; Fiuji H; Shafiee M; Ferns GA; Avan A; Hassanian SM
    Int J Biochem Cell Biol; 2020 Jul; 124():105765. PubMed ID: 32428568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
    Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
    Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
    Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
    Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A microRNA expression profile for vascular invasion can predict overall survival in hepatocellular carcinoma.
    Lin Z; Cai YJ; Chen RC; Chen BC; Zhao L; Xu SH; Wang XD; Song M; Wu JM; Wang YQ; Zhou MT; Shi KQ
    Clin Chim Acta; 2017 Jun; 469():171-179. PubMed ID: 28365450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput mRNA and miRNA profiling of epithelial-mesenchymal transition in MDCK cells.
    Shukla P; Vogl C; Wallner B; Rigler D; Müller M; Macho-Maschler S
    BMC Genomics; 2015 Nov; 16():944. PubMed ID: 26572553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development.
    Aswad L; Yenamandra SP; Ow GS; Grinchuk O; Ivshina AV; Kuznetsov VA
    Oncotarget; 2015 Nov; 6(34):36652-74. PubMed ID: 26474389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.